GlassScriptPhysician profile
Michele Uematsu
NPI 1811748239
$3,853.71
in general payments reported to CMS, 2019-2025
41 companies · $3,082 in 2025
The $3,082 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.41 · 2023: $40.36 · 2024: $715 · 2025: $3,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,363 · Consulting Fee: $375 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,363.30 |
| Consulting Fee | $375.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caris Mpi, INC. | $625.90 | 2025 | Mi Cancer Seek |
| Abbvie INC. | $298.85 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $263.52 | 2023-2025 | Imfinzi, Enhertu |
| Pfizer INC. | $251.52 | 2022-2025 | |
| Astellas Pharma US INC | $234.76 | 2024-2025 | Xtandi, Vyloy, Padcev |
| Daiichi Sankyo INC. | $191.67 | 2024-2025 | Vanflyta, Enhertu |
| Novartis Pharmaceuticals Corporation | $164.95 | 2024-2025 | |
| Biomarin Pharmaceutical INC. | $119.86 | 2025 | Roctavian |
| Janssen Biotech, INC. | $119.22 | 2024-2025 | Erleada, Carvykti |
| Azurity Pharmaceuticals, INC. | $106.93 | 2025 | Danziten |
| Seagen INC. | $99.00 | 2025 | |
| Incyte Corporation | $94.07 | 2025 | Jakafi, Niktimvo |
| Exelixis INC. | $90.89 | 2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $84.17 | 2025 | Keytruda, Welireg, Lynparza |
| Tersera Therapeutics LLC | $74.55 | 2025 | Zoladex |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Uematsu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.